Nomic Bio ads

Detecting toxicity early is essential. Understanding what’s driving it is just as important. Sensitive toxicity assessment requires researchers to detect early compound-induced changes while determining the biological mechanisms underlying those responses. Conventional assays may identify overt toxicity without providing mechanistic context. High-plex protein profiling offers an opportunity to characterize concentration-dependent molecular responses and connect early toxicity signals with compound mode of action. In this upcoming webinar, Jess Ewald, PhD (EMBL-EBI), and Nathaniel Robichaud, PhD (Nomic Bio), discuss how data from Health and Environmental Sciences Institute (HESI) Global’s OASIS Consortium can reveal early toxicity signals and connect them with compound mode of action. November 5 | 11 AM ET | 8 AM PT | 5 PM CET Register here: https://hubs.ly/Q04yLM0_0 #Proteomics #Toxicity #DrugSafety #OASISConsortium #HESIGlobal

Applications are now open for Nomic’s Fibrosis Proteomics Grant! Fibrosis is a major driver of disease progression and organ failure across the liver, lung, kidney, heart, and other tissues. Despite its enormous clinical impact, the mechanisms that determine why fibrosis develops, progresses, or resolves remain incompletely understood. Because fibrosis is driven by complex, interconnected signaling networks, its biology cannot be fully captured by measuring only a handful of biomarkers. Researchers need broad, quantitative coverage of the proteins regulating the disease. Nomic Omni 1000 enables that view with absolute quantification of 1,063 proteins, including 177 fibrosis-associated proteins spanning TGF-β signaling, extracellular matrix remodeling, collagen maturation, myofibroblast activation, cytokine signaling, and organ-specific injury. To help accelerate new discoveries in fibrosis biology, we’re awarding Nomic Omni 1000 profiling for up to 1,152 samples, along with access to the Nomic Data Portal, technical support, and scientific collaboration throughout the project. Submit a 250-word proposal by October 5, 2026. Learn more and apply: https://hubs.ly/Q04sLZX-0 #fibrosis #proteomics #nomic #highthroughput #biomarkerdiscovery

One week to go! Join Amanda McQuade, PhD (Martin Kampmann Lab, UCSF), and Nathaniel Robichaud, PhD (Nomic Bio) to learn how protein-level biology can improve the interpretation of CRISPR screens and provide functional insights that transcriptomics alone may miss. Be sure to stick around after the presentations for a live Q&A! Using disease-associated microglial activation states as an example, we'll explore how protein-level data can help researchers better understand the biology downstream of genetic perturbations and strengthen target validation. 📅 July 15 | 11:00 AM ET 🔗 Register here: https://hubs.ly/Q04nWSKW0

Today we announced our partnership with Broad Clinical Labs. They’ll be integrating Omni 1000 into their discovery and translational workflows, bringing Nomic’s proteomics platform into a new multi-omic environment. If you’re working in this space, you know the gaps. Multi-omic programs are becoming standard, but proteomics hasn’t been as easy to run at the same scale as other modalities, and the data generated is just not inter-operable. That’s what this partnership is all about. By deploying Omni 1000, Broad Clinical Labs will generate high-plex, absolutely quantitative proteomic data, establishing a foundation for entirely new multi-omic applications that were previously inaccessible across discovery and translational research. More to come. Read the full announcement: https://lnkd.in/ezVAGry7 #nomic #broadclinicallabs #proteomics #multiomics #translationalresearch #proteinprofiling #nELISA

Does RNA-seq have a blind spot in perturbation screens? 👋 The secretome has entered the chat. In this 8 minute video, Nathaniel Robichaud, PhD, walks through what we see when we directly measure cytokines across ~7,000 PBMC perturbations. Short clip below. 🎥 Full video: https://lnkd.in/eh4RiRue

🚨 Explore immune perturbations in a completely new light through functional proteomics. We’re excited to share the Perturb-PBMC dataset, released alongside our Nature Methods paper and now available through the Nomic Data Portal (link below). We perturbed PBMCs from healthy donors with 80 cytokine immunomodulators, and read out ~200 secreted proteins - one of the largest functional proteomic screens ever performed. Through the Portal, you can interactively explore this data - seeing how human immune cells respond to diverse stimuli at the protein level. 🔍 Explore questions like: • What aspects of the secretome differ widely from transcriptome-based expectations? • Which interactions are highly donor-dependent? • How can functional proteomics reveal new therapeutic opportunities? We’ve built the foundation. Now it’s your turn to explore and make the next discovery. 🔗 Read the article to learn more: https://lnkd.in/eCf8h9yZ 🔗 Explore the dataset in the Nomic Data Portal: https://lnkd.in/etvACXbC